

HR 4821

Fair Advertising and Increased Research (FAIR) Act

Congress: 107 (2001–2003, Ended)

Chamber: House

Policy Area: Taxation

Introduced: May 22, 2002

Current Status: Referred to the House Committee on Ways and Means.

Latest Action: Referred to the House Committee on Ways and Means. (May 22, 2002)

Official Text: <https://www.congress.gov/bill/107th-congress/house-bill/4821>

Sponsor

Name: Rep. Pallone, Frank, Jr. [D-NJ-6]

Party: Democratic • **State:** NJ • **Chamber:** House

Cosponsors (19 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Allen, Thomas H. [D-ME-1]	D · ME		May 22, 2002
Rep. Berry, Marion [D-AR-1]	D · AR		May 22, 2002
Rep. Brown, Sherrod [D-OH-13]	D · OH		May 22, 2002
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		May 22, 2002
Rep. Gephardt, Richard A. [D-MO-3]	D · MO		May 22, 2002
Rep. Langevin, James R. [D-RI-2]	D · RI		May 22, 2002
Rep. Rodriguez, Ciro D. [D-TX-28]	D · TX		May 22, 2002
Rep. Sanders, Bernard [I-VT-At Large]	I · VT		May 22, 2002
Rep. Stark, Fortney Pete [D-CA-13]	D · CA		May 22, 2002
Rep. Strickland, Ted [D-OH-6]	D · OH		May 22, 2002
Rep. Wexler, Robert [D-FL-19]	D · FL		May 22, 2002
Rep. Wynn, Albert Russell [D-MD-4]	D · MD		May 22, 2002
Rep. Crowley, Joseph [D-NY-7]	D · NY		Jun 25, 2002
Rep. Davis, Danny K. [D-IL-7]	D · IL		Jun 25, 2002
Rep. DeFazio, Peter A. [D-OR-4]	D · OR		Jun 25, 2002
Rep. Kucinich, Dennis J. [D-OH-10]	D · OH		Jun 25, 2002
Rep. Rivers, Lynn N. [D-MI-13]	D · MI		Jun 25, 2002
Rep. Israel, Steve [D-NY-2]	D · NY		Jul 17, 2002
Rep. Slaughter, Louise McIntosh [D-NY-28]	D · NY		Sep 26, 2002

Committee Activity

Committee	Chamber	Activity	Date
Ways and Means Committee	House	Referred To	May 22, 2002

Subjects & Policy Tags

Policy Area:

Taxation

Related Bills

Bill	Relationship	Last Action
107 S 2486	Companion bill	Jul 18, 2002: Sponsor introductory remarks on measure. (CR S6968-6969)

Summary (as of May 22, 2002)

Fair Advertising and Increased Research Act - Amends the Internal Revenue Code to prohibit any drug manufacturer from taking a tax deduction for expenditures relating to the advertising, promoting, or marketing of any FDA prescription drug to the extent the aggregate amount of such expenditures exceeds the manufacturer's aggregate research and development expenditures.

Directs the Secretary of the Treasury to estimate amount of additional tax revenues raised by enforcement of the Act, to be allocated to the Federal Hospital Insurance Trust Fund.

Actions Timeline

- **May 22, 2002:** Introduced in House
- **May 22, 2002:** Introduced in House
- **May 22, 2002:** Referred to the House Committee on Ways and Means.
- **May 20, 2002:** Sponsor introductory remarks on measure. (CR H2651)